1525. Evaluation of Clinical Outcomes With Fosfomycin for E. coli and Non-E. coli Enterobacteriaceae Urinary Tract Infections

摘要

BackgroundFosfomycin is a broad-spectrum oral antibiotic increasingly used for the treatment of uncomplicated and complicated urinary tract infections (UTIs). The Clinical and Laboratory Standards Institute (CLSI) does not support fosfomycin susceptibility testing on urinary isolates outside of Enterococcus faecalis and Escherichia coli. This is in light of building evidence and concern for the presence of chromosomal fosA gene in non-E. coli Enterobacteriaceae. Regardless, clinicians have continued to test and use fosfomycin for these pathogens due to multidrug resistance or intolerance to other agents without ample data on clinical implications.